Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
IL |
|
Y
|
Yantai Changyu Pioneer Wine Co Ltd
SZSE:000869
|
CN |
|
Sona Topas Tourism Industry Tbk PT
IDX:SONA
|
ID |
|
Eros Media World PLC
OTC:EMWPF
|
AE |
|
Maha Properti Indonesia Tbk PT
IDX:MPRO
|
ID |
|
Majestic Gold Corp
XTSX:MJS
|
CA |
|
DecisionPoint Systems Inc
F:RS7
|
US |
|
H
|
Hup Seng Industries Bhd
KLSE:HUPSENG
|
MY |
|
A
|
Able Global Bhd
KLSE:ABLEGLOB
|
MY |
|
Wintrust Financial Corp
NASDAQ:WTFC
|
US |
|
Hirakawa Hewtech Corp
TSE:5821
|
JP |
|
Openpay Group Ltd
ASX:OPY
|
AU |
|
Rajnandini Metal Ltd
NSE:RAJMET
|
IN |
|
Saudi Arabian Cooperative Insurance Company SJSC
SAU:8100
|
SA |
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
CN |
|
A
|
Abbott India Ltd
NSE:ABBOTINDIA
|
IN |
|
F
|
FAE Technology SpA SB
MIL:FAE
|
IT |
|
Grupo Financiero Inbursa SAB de CV
OTC:GPFOF
|
MX |
|
Verisign Inc
NASDAQ:VRSN
|
US |
|
S
|
Solid FAB
STO:SFAB
|
SE |
|
P
|
Protean eGov Technologies Ltd
BSE:544021
|
IN |
|
C
|
Core Assets Corp
CNSX:CC
|
CA |
|
H
|
Hebei Yangyuan ZhiHui Beverage Co Ltd
SSE:603156
|
CN |
|
R
|
Rajratan Global Wire Ltd
NSE:RAJRATAN
|
IN |
Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
